期刊
ACTA DERMATO-VENEREOLOGICA
卷 96, 期 5, 页码 579-+出版社
ACTA DERMATO-VENEREOLOGICA
DOI: 10.2340/00015555-2335
关键词
rosacea; erythema; brimonidine; patho-physiology; vasculature; treatment
类别
资金
- Galderma
- LaRoche Posay
- GSK
- Leo Pharm
- Bayer
- Regeneron
- Pfizer
- Avon
- L'Oreal
- LaRoche Pasay
- Noxxon
- Galderma Laboratories LP
Rosacea is a common chronic skin condition that displays a broad diversity of clinical manifestations. Although the pathophysiological mechanisms of the 4 subtypes are not completely elucidated, the key elements often present are augmented immune responses of the innate and adaptive immune system, and neurovascular dysregulation. The most common primary feature of all cutaneous sub-types of rosacea is transient or persistent facial erythema. Perilesional erythema of papules or pustules is based on the sustained vasodilation and plasma extravasation induced by the inflammatory infiltrates. In contrast, transient erythema has rapid kinetics induced by trigger factors independent of papules or pustules. Amongst the current treatments for facial erythema of rosacea, only the selective alpha(2)-adrenergic receptor agonist brimonidine 0.33% topical gel (Mirvaso (R)) is approved. This review aims to discuss the potential causes, different pathophysiologies and current treatment options to address the unmet medical needs of patients with facial erythema of rosacea.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据